Understanding and preventing heart problems in children with acute myeloid leukemia
Official title: Predicting and Monitoring for Cardiac Toxicity in Pediatric AML
Funded at Children's Hosp of Philadelphia · NIH-10913999 · Data updated 2026-11-12
This study is looking at how to keep kids with acute myeloid leukemia safe from heart problems that can happen because of their chemotherapy, and it aims to find ways to spot those risks early so doctors can help them better during treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 25, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $622,359 |
| NIH project number | 5R01HL163657-02 |
| Project ID | NIH-10913999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who are newly diagnosed with acute myeloid leukemia and are about to begin chemotherapy treatment.
✕Less likely to help
Patients who are older than 11 years or those who have already completed treatment for AML may not benefit from this research.
What this research studies
This research focuses on children diagnosed with acute myeloid leukemia (AML) and aims to predict and monitor heart-related complications caused by chemotherapy treatments, specifically anthracyclines. The study will analyze clinical data to develop models that can identify patients at risk for cardiac toxicity early in their treatment. By closely monitoring heart function during therapy, the research seeks to improve patient outcomes and reduce the risk of severe heart issues. The approach involves using advanced algorithms and clinical trial data to create effective prediction tools.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and management of heart health in children undergoing treatment for AML, ultimately improving survival rates and quality of life.
How similar studies have gone: Previous research has shown that monitoring cardiac health in childhood cancer survivors can be beneficial, but this specific approach for newly diagnosed AML patients is novel and untested.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Aplenc, Richard — Children's Hosp of Philadelphia
- Study coordinator: Aplenc, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.